Superficial vein thrombosis (superficial thrombophlebitis)
Exam Tips
- In OSCEs, always state that SVT can coexist with DVT/PE and that duplex ultrasound is used to map clot length and proximity to the saphenofemoral junction.
- Red flags for anticoagulation/escalation: thrombus >=5 cm, above-knee involvement, near saphenofemoral junction, extensive calf+thigh disease, active cancer, prior VTE, or absent varicose veins.
- Do not use D-dimer to rule in/out isolated SVT in primary assessment.
- Quote a UK-ready regimen: fondaparinux 2.5 mg SC once daily for 45 days in appropriate patients.
- Safety warnings to mention in viva: anticoagulants are contraindicated in active major bleeding; use caution/adjustment in renal impairment; avoid NSAIDs in peptic ulcer disease, severe CKD, uncontrolled hypertension, heart failure, or anticoagulant co-prescribing without risk review.
- Image cue for revision: review a lower-limb venous anatomy figure showing great saphenous vein, perforators, and saphenofemoral junction to explain why proximal clot location alters management.
Definition
Superficial vein thrombosis (SVT, superficial thrombophlebitis) is thrombus formation with inflammation in a superficial vein, most often in lower-limb varicose tributaries or the great/small saphenous system. Although often viewed as a local venous problem, it sits on a venous thromboembolism spectrum because clot can extend or coexist with deep vein thrombosis (DVT) and occasionally pulmonary embolism (PE).
Pathophysiology
SVT develops through Virchow-triad mechanisms (venous stasis, endothelial injury, hypercoagulability), with varicose-vein flow disturbance being the commonest trigger in primary care. Endothelial activation and local cytokine release promote thrombin generation, fibrin-rich clot, and perivenous inflammation, producing a tender palpable cord. Anatomically, risk rises when thrombus is in the main saphenous trunk, long segments (especially >=5 cm), above-knee disease, or close to the saphenofemoral junction, where propagation into deep veins is more likely.
Risk Factors
- Varicose veins (most common; present in most lower-limb SVT cases)
- Increasing age
- Obesity/overweight
- Previous SVT or previous VTE
- Active malignancy (including migratory thrombophlebitis/Trousseau pattern)
- Pregnancy and puerperium (up to 6 weeks postpartum)
- Combined hormonal contraception or oral HRT
- Recent surgery or prolonged immobility
- Intravenous cannulation/infusion, venepuncture, or irritant sclerosant exposure
- Autoimmune/inflammatory vasculopathic disease (for example Behcet disease, Buerger disease, SLE)
- Inherited/acquired thrombophilia (for example factor V Leiden, protein C/S deficiency)
Clinical Features
Symptoms
- Localized limb pain/tenderness along a superficial vein
- Itch over affected segment
- Symptoms evolving over hours to days
- Occasional surrounding swelling or discomfort on walking/standing
Signs
- Palpable, firm, tender cord or lump along a superficial vein (often varicose territory)
- Overlying erythema and warmth
- Possible brown haemosiderin pigmentation over days to weeks
- Coexisting varicose veins/chronic venous insufficiency signs (oedema, skin changes, venous eczema/ulcer history)
- Features suggesting complication: whole-leg swelling, calf tenderness, pleuritic chest pain, dyspnoea, fever, purulent track (consider DVT/PE or infection)
Investigations
Management
Lifestyle Modifications
- Mobilize and avoid prolonged immobility if clinically safe
- Leg elevation and warm compresses for symptom relief
- Graduated compression hosiery may improve pain/oedema when tolerated and no significant peripheral arterial disease is present
- Safety-net urgently for PE/DVT symptoms (new breathlessness, pleuritic pain, haemoptysis, increasing leg swelling)
Pharmacological Treatment
Anticoagulation for higher-risk lower-limb SVT
- Fondaparinux 2.5 mg subcutaneously once daily for 45 days
Common UK first-line option for symptomatic SVT >=5 cm and not immediately adjacent to deep junctions; assess bleeding risk, renal function, weight, and pregnancy status before prescribing.
Alternative anticoagulation when fondaparinux unsuitable (specialist/local protocol)
- Enoxaparin 40 mg subcutaneously once daily (prophylactic dosing)
- Dalteparin 5000 units subcutaneously once daily (prophylactic dosing)
Used in some pathways; dose may vary by indication, renal function, and weight. If thrombus is very near the saphenofemoral junction or DVT is present, treat as VTE with full-dose anticoagulation per DVT protocol.
Analgesia/anti-inflammatory therapy
- Ibuprofen 400 mg orally three times daily with food (short course)
- Naproxen 250-500 mg orally twice daily
- Paracetamol 1 g orally up to four times daily (max 4 g/day)
NSAIDs reduce pain/inflammation in low-risk localized disease but do not replace anticoagulation when extension risk is high. Use lowest effective NSAID dose for shortest duration.
Surgical / Interventional
- Urgent vascular/surgical assessment if suppurative thrombophlebitis, abscess, or progressive septic features
- Definitive varicose vein intervention (for example endovenous ablation/ligation-stripping) can be considered after acute episode settles to reduce recurrence in selected patients
Complications
- Concurrent or subsequent DVT
- Pulmonary embolism
- Thrombus extension along superficial trunk veins
- Recurrent SVT (including migratory thrombophlebitis)
- Local infection, cellulitis, abscess, and rarely sepsis (especially cannula-related)
- Persistent pain/induration and chronic venous morbidity
Prognosis
Most patients improve clinically over days to weeks, but venous induration can persist for weeks to months. Thromboembolic risk is highest early and remains clinically relevant for at least 3 months, particularly with proximal, long-segment, non-varicose, cancer-associated, or prior-VTE disease. Mortality is low overall, but missed progression to DVT/PE is the key avoidable harm.
Sources & References
💊BNF Drug References(1)
- Fondaparinux sodium[management.pharmacological]
✅NICE Guidelines(1)
📖Textbook References(6)
- David Randall PhD MRCP (Editor), John Booth PhD MRCP (Editor), K - Kumar and Clark's Clinical Medicine (2025, American Elsevier Publishing Co.) - libgen.li.pdf(pp. 298, 299)[context]
- David Randall PhD MRCP (Editor), John Booth PhD MRCP (Editor), K - Kumar and Clark's Clinical Medicine (2025, American Elsevier Publishing Co.) - libgen.li.pdf(pp. 298)[context]
- David Randall PhD MRCP (Editor), John Booth PhD MRCP (Editor), K - Kumar and Clark's Clinical Medicine (2025, American Elsevier Publishing Co.) - libgen.li.pdf(pp. 535, 536)[context]
- David Randall PhD MRCP (Editor), John Booth PhD MRCP (Editor), K - Kumar and Clark's Clinical Medicine (2025, American Elsevier Publishing Co.) - libgen.li.pdf(pp. 535, 536)[context]
- David Randall PhD MRCP (Editor), John Booth PhD MRCP (Editor), K - Kumar and Clark's Clinical Medicine (2025, American Elsevier Publishing Co.) - libgen.li.pdf(pp. 536, 537)[context]
- David Randall PhD MRCP (Editor), John Booth PhD MRCP (Editor), K - Kumar and Clark's Clinical Medicine (2025, American Elsevier Publishing Co.) - libgen.li.pdf(pp. 297, 298)[context]